Better and faster bronchodilator delivery for sustained improvement of COPD symptoms

Chronic Obstructive Pulmonary Disease (COPD), one of the most serious lung diseases prevalent today, affects 65 million people worldwide. In India, it was the second highest cause of death in 2017, killing nearly one million Indians that year, according to University of Washington’s Global Burden of Disease Study, 2018.

Aerogen, a multi-award winning global company, founded in Ireland 1997, has developed ground-breaking technology for hospital patients with respiratory illness, such as COPD, Asthma and Cystic Fibrosis.

Currently used by over 7 million patients worldwide, Aerogen’s flagship products, the Aerogen Solo and Aerogen Ultra, are based on unique palladium vibrating mesh technology, Aerogen Vibronic®, ensuring optimised bronchodilator delivery during exacerbation of COPD.


6 x more medication to the lungs compared to a jet nebulizer’ resulting in improved and visible patient response to treatment2

Small volume nebulizer1

Aerogen Ultra1


85% patients achieved symptom control with one 2.5mg albuterol dose3
Faster patient response to treatment2

Patients responded to a single albuterol dose


Sustained improvement in FEV1% and PEFR% over time compared to jet nebulizers.2

  • Reduced median length of stay in th ED3
  • Reduced ED admissions.3
  • Increased throughput.3

Download study poster by Royal College of Surgeons Ireland (RCSI), showing benefits of using vibrating mesh nebulizers in the treatment of COPD exacerbations.